← 返回

Pescadillo 核糖体生物发生因子 1 作为肿瘤免疫治疗的治疗靶点

英文原题:Pescadillo ribosomal biogenesis factor 1 as a therapeutic target in tumor immunotherapy.

查看英文原题

Pescadillo ribosomal biogenesis factor 1 as a therapeutic target in tumor immunotherapy.

PubMed 2025/11/07(内容时间) World J Gastroenterol Q1 · IF 7.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

PES1(pescadillo核糖体生物发生因子1)在多种癌症类型中高表达,并与不良预后显著相关。Hu等人近期发表的论文描述了他们对PES1在胃癌和头颈部鳞状细胞癌中的研究,证明PES1与PD-L1表达呈正相关(PES1为51.72%,PD-L1为58.62%),并与淋巴结转移和肿瘤浸润深度相关。然而,PES1与PD-L1之间的关系仍未完全明确。为进一步填补这一空白,我们分析了癌症基因组图谱胃腺癌数据集,发现PES1表达与CD8+ T细胞浸润呈负相关,同时与PD-L1表达呈正相关。基于既往发现,我们假设PES1可能通过磷脂酰肌醇3-激酶/蛋白激酶B通路或细胞Myc介导的机制调控PD-L1。虽然这些通路需要实验验证,但我们的观察结果突显了PES1作为免疫逃逸的潜在调控因子以及癌症免疫治疗的有前景靶点。

展开英文摘要原文

High expression of pescadillo ribosomal biogenesis factor 1 (PES1) has been reported across multiple cancer types and is significantly associated with poor prognosis. Hu et al in their recent paper described their investigation of PES1 in gastric cancer and head and neck squamous cell carcinoma, demonstrating positive correlations between PES1 and programmed death-ligand 1 (PD-L1) expression (51. 72% for PES1 and 58. 62% for PD-L1), as well as associations with lymph node metastasis and tumor invasion depth.

However, the relationship between PES1 and PD-L1 remains incompletely defined. To further address this gap, we analyzed The Cancer Genome Atlas gastric adenocarcinoma dataset and found a negative correlation between PES1 expression and CD8+ T cell infiltration, alongside a positive correlation with PD-L1 expression.

Based on prior findings, we hypothesize that PES1 may regulate PD-L1 through the phosphatidylinositol 3-kinase/protein kinase B pathway or cellular Myc-mediated mechanisms. While these pathways require experimental validation, our observations highlight PES1 as a potential regulator of immune evasion and a promising target for cancer immunotherapy.

论文信息

作者
Yu J、Yu B、Ge FL、Ren ZG
第一作者单位
Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.China
通讯作者单位
Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China. fccrenzg@zzu.edu.cn.China
文献类型
读者来信
期刊
World journal of gastroenterology2025 Nov 7
原文标识
PubMed 41257272 · DOI 10.3748/wjg.v31.i41.110367